logo
Plus   Neg
Share
Email

Zynga Slips To Loss In Q4 - Quick Facts

Zynga Inc. (ZNGA) reported that its fourth-quarter net loss attributable to common stockholders was $435.01 million, compared to net income of $16.06 million in the same quarter last year. On per share basis, net loss for the quarter was $1.22 compared to net income of $0.05 for the fourth quarter of 2010.

The latest quarter results included $510 million of stock-based compensation expense for restricted stock units issued to employees that was previously unrecognized until triggered by initial public offering.

Non-GAAP earnings per share was $0.05 for the fourth quarter of 2011 compared to $0.09 for the fourth quarter of 2010.

Total Revenue was $311.24 million up from $195.76 million in the year ago quarter. Bookings were at a record level of $306.5 million for the fourth quarter of 2011, an increase of 26% compared to the fourth quarter of 2010 and an increase of 7% compared to the third quarter of 2011.

Looking ahead for fiscal 2012, non-GAAP earnings per share is projected to be in the range of $0.24 to $0.28. Bookings are projected to be in the range of $1.35 billion to $1.45 billion.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT